The estimated Net Worth of Capital, Llc Boyd Steven Ar... is at least 53.2 百万$ dollars as of 9 January 2019. Capital Ar owns over 13,996 units of Cerecor Inc stock worth over 53,237,511$ and over the last 6 years Capital sold CERC stock worth over 0$.
Capital has made over 4 trades of the Cerecor Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Capital bought 13,996 units of CERC stock worth 54,304$ on 9 January 2019.
The largest trade Capital's ever made was buying 55,900 units of Cerecor Inc stock on 3 January 2019 worth over 430,430$. On average, Capital trades about 35,250 units every 2 days since 2019. As of 9 January 2019 Capital still owns at least 18,169,799 units of Cerecor Inc stock.
You can see the complete history of Capital Ar stock trades at the bottom of the page.
Capital's mailing address filed with the SEC is 22nd Floor, 510 Madison Ave, New York, NY 10022, United States.
Over the last 9 years, insiders at Cerecor Inc have traded over 0$ worth of Cerecor Inc stock and bought 18,463,844 units worth 43,946,959$ . The most active insiders traders include Forest Baskett、Scott D Sandell、Capital, Llc Armistice Capi.... On average, Cerecor Inc executives and independent directors trade stock every 19 days with the average trade being worth of 601,142$. The most recent stock trade was executed by Capital, Llc Armistice Capi... on 16 August 2021, trading 50,000 units of CERC stock currently worth 138,000$.
Cerecor is a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare and orphan diseases. The company is advancing its clinical-stage pipeline of innovative therapies that address unmet patient needs within rare and orphan diseases. The company's rare disease pipeline includes CERC-801, CERC-802 and CERC-803, which are in development for congenital disorders of glycosylation and CERC-006, an oral mTORc1/c2 inhibitor in development for the treatment of complex lymphatic malformations. The company is also developing two monoclonal antibodies, CERC-002, and CERC-007. CERC-002 targets the cytokine LIGHT (TNFSF14) and is in clinical development for treatment of severe pediatric-onset Crohn's disease, and COVID-19 acute respiratory distress syndrome. CERC-007 targets the cytokine IL-18 and is in clinical development for the treatment of Still's disease (adult onset Still's disease (AOSD) and systemic juvenile idiopathic arthritis (sJIA)), and multiple myeloma (MM). CERC-006, 801, 802 and 803 have all received Orphan Drug Designation and Rare Pediatric Disease Designation, which makes all four eligible for a priority review voucher upon FDA approval.
Cerecor Inc executives and other stock owners filed with the SEC include: